Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randall J Bateman

Showing results (81-90 of 391) with videos related to

Pageof 40
Sort By:
Alzheimer'S & Dementia (New York, N. Y.)|April 13, 2022
Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's diseaseGuoqiao Wang, Lei Liu, Yan Li, et al.
Science (New York, N.Y.)|September 26, 2009
Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycleJae-Eun Kang, Miranda M Lim, Randall J Bateman, et al.
Journal of Alzheimer'S Disease : JAD|June 30, 2025
Harnessing greater statistical power: Comprehensive evaluation of disease modifying treatment effects across all or multiple post-baseline visits compared to the last visit for Alzheimer's disease clinical trialsGuoqiao Wang, Tianle Chen, John O'Gorman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentJorge J Llibre-Guerra, Jin Zhou, Lon S S Schneider, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentJin Zhou, Erica Andreozzi, Jorge J Llibre-Guerra, et al.
Alzheimer'S & Dementia (New York, N. Y.)|September 14, 2019
Two-period linear mixed effects models to analyze clinical trials with run-in data when the primary outcome is continuous: Applications to Alzheimer's diseaseGuoqiao Wang, Andrew J Aschenbrenner, Yan Li, et al.
Brain Communications|April 13, 2022
A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer's diseaseMelissa M Budelier, Yingxin He, Nicolas R Barthelemy, et al.
Science Translational Medicine|December 16, 2016
Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injuryMarc Suárez-Calvet, Miguel Ángel Araque Caballero, Gernot Kleinberger, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|January 16, 2022
Interactions Between Weight Loss and Plasma Neurodegenerative Markers for Determining Cognitive Decline Among Community-Dwelling Older AdultsKelly Virecoulon Giudici, Sophie Guyonnet, John E Morley, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 13, 2024
The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidencePaul Aisen, Randall J Bateman, Damian Crowther, et al.
Pageof 40

Showing results (81-90 of 391) with videos related to

Sort By:
Pageof 40
Alzheimer'S & Dementia (New York, N. Y.)|April 13, 2022
Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's diseaseGuoqiao Wang, Lei Liu, Yan Li, et al.
Science (New York, N.Y.)|September 26, 2009
Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycleJae-Eun Kang, Miranda M Lim, Randall J Bateman, et al.
Journal of Alzheimer'S Disease : JAD|June 30, 2025
Harnessing greater statistical power: Comprehensive evaluation of disease modifying treatment effects across all or multiple post-baseline visits compared to the last visit for Alzheimer's disease clinical trialsGuoqiao Wang, Tianle Chen, John O'Gorman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentJorge J Llibre-Guerra, Jin Zhou, Lon S S Schneider, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentJin Zhou, Erica Andreozzi, Jorge J Llibre-Guerra, et al.
Alzheimer'S & Dementia (New York, N. Y.)|September 14, 2019
Two-period linear mixed effects models to analyze clinical trials with run-in data when the primary outcome is continuous: Applications to Alzheimer's diseaseGuoqiao Wang, Andrew J Aschenbrenner, Yan Li, et al.
Brain Communications|April 13, 2022
A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer's diseaseMelissa M Budelier, Yingxin He, Nicolas R Barthelemy, et al.
Science Translational Medicine|December 16, 2016
Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injuryMarc Suárez-Calvet, Miguel Ángel Araque Caballero, Gernot Kleinberger, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|January 16, 2022
Interactions Between Weight Loss and Plasma Neurodegenerative Markers for Determining Cognitive Decline Among Community-Dwelling Older AdultsKelly Virecoulon Giudici, Sophie Guyonnet, John E Morley, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 13, 2024
The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidencePaul Aisen, Randall J Bateman, Damian Crowther, et al.
Pageof 40